Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2010:926192.
doi: 10.1155/2010/926192. Epub 2010 May 23.

Bimatoprost effects on aqueous humor dynamics in monkeys

David F Woodward  1 , Achim H-P Krauss, Siv F E Nilsson
Affiliations

Bimatoprost effects on aqueous humor dynamics in monkeys

David F Woodward et al. J Ophthalmol. 2010.

Abstract

The effects of bimatoprost on aqueous humor dynamics were quantified in monkey eyes. Uveoscleral outflow was measured by the anterior chamber perfusion method, using FITC-dextran. Total outflow facility was determined by the two-level constant pressure method. Aqueous flow was measured with a scanning ocular fluorophotometer. Uveoscleral outflow was 0.96 +/- 0.19 muL min(-1) in vehicle-treated eyes and 1.37 +/- 0.27 muL min(-1) (n = 6; P < .05) in eyes that received bimatoprost 0.01% b.i.d. x 5 days. Bimatoprost had no effect on total outflow facility, which was 0.42 +/- 0.05 muL min(-1) at baseline and 0.42 +/- 0.04 muL min(-1) after bimatoprost treatment. Bimatoprost had no significant effect on aqueous humor flow. This study demonstrates that bimatoprost increases uveoscleral outflow but not total outflow facility or aqueous humor flow, indicating that it lowers intraocular pressure in ocular normotensive monkeys by a mechanism that exclusively involves uveoscleral outflow.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Woodward DF, Krauss AH-P, Chen J, et al. Pharmacological characterization of a novel anti-glaucoma agent, bimatoprost (AGN 192024) Journal of Pharmacology and Experimental Therapeutics. 2003;305(2):772–785. - PubMed
    1. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Archives of Ophthalmology. 2002;120:1286–1293. - PubMed
    1. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Survey of Ophthalmology. 2001;45(supplement 4):5323–5360. - PubMed
    1. Whitcup SM, Cantor LB, VanDenburgh AM, Chen K. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. British Journal of Ophthalmology. 2003;87:59–62. - PMC - PubMed
    1. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the introcular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. American Journal of Ophthalmology. 2003;135:55–63. - PubMed